# Financial Results for FY2021 Second Quarter 

October 27, 2021

SUMITOMO CHEMICAL

## (Cautionary Statement)

Statements made in this material with respect to Sumitomo Chemical's current plans, estimates, strategies and beliefs that are not historical facts are forward-looking statements about the future performance of Sumitomo Chemical. These statements are based on management's assumptions and beliefs in light of the information currently available to it, and involve risks and uncertainties. The important factors that could cause actual results to differ materially from those discussed in the forward-looking statements include, but are not limited to, general economic conditions in Sumitomo Chemical's markets; demand for, and competitive pricing pressure on, Sumitomo Chemical's products in the marketplace;
Sumitomo Chemical's ability to continue to win acceptance for its products in these highly competitive markets; and movements of currency exchange rates.

## Contents

1.Financial Results for FY2021 Second Quarter
Financial Summary ..... 4
Sales Revenue by Business Segment ..... 5
Core Operating Income by Business Segment ..... 6
Segment Analysis ..... 7
Breakdown of Non-recurring Items ${ }^{-}$ ..... 12
Consolidated Balance Sheets ..... 13
Consolidated Statements of Cash Flows ..... 14
2. Outlook for FY2021
Financial Estimates for Year ..... 16
Sales Revenue and Core Operating Income by Business Segment ..... 17
(Reference: Segment Information)
Cost Elements etc. ..... 19
Capital Expenditures
by Business Segment ..... 20
Depreciation and Amortization by Business Segment ..... 21
Research \& Development Expenses by Business Segment ..... 22
Sales Revenue
by Business Segment (Quarterly) ..... 23
Core Operating Income by Business Segment (Quarterly) ..... 24
Major Group Companies ..... 25
Crop Protection Product Sales by Region ..... 26

## 1. Financial Results for FY2021 Second Quarter

- SUMITTOMO CHEMICAL


## Financial Summary

|  | Unit; Billions of yen |  |  |  |
| :---: | :---: | :---: | :---: | :---: |
|  | $\begin{gathered} \text { FY2020 } \\ \text { 2nd Quarter } \end{gathered}$ | $\begin{gathered} \text { FY2021 } \\ \text { 2nd Quarter } \end{gathered}$ | Difference | Ratio |
| Sales revenue | 1,046.8 | 1,325.2 | 278.4 | 26.6\% |
| Core operating income (Equity in earnings) | $\begin{array}{r} 53.5 \\ (-23.0) \end{array}$ | $\begin{aligned} & 148.9 \\ & (27.2) \end{aligned}$ | $\begin{array}{r} 95.4 \\ (50.2) \end{array}$ | $178.4 \%$ |
| Non-recurring items | -3.3 | -4.6 | -1.3 | - |
| Operating income | 50.2 | 144.3 | 94.1 | 187.5\% |
| Finance income/expenses | -11.9 | 2.5 | 14.4 | - |
| (Gain/loss on foreign currency transactions) | (-9.0) | (6.0) | (15.0) | - |
| Income tax expenses | -24.0 | -39.0 | -15.0 | - |
| Net income attributable to non-controlling interests | -16.5 | -18.9 | -2.4 | - |
| Net income attributable to owners of the parent | -2.2 | 88.9 | 91.1 | - |
| ROE | -0.2\% | 8.5\% |  |  |
| Exchange rate(yen/\$) | 106.93 | 109.81 |  |  |
| Naphtha price(yen/KL) | 27,600 | 50,600 |  |  |
| Overseas sales revenue ratio | 68.7\% | 67.1\% |  |  |

※ During FY 2020, we finalized the provisional accounting treatment for business combinations.
As a result, figures for FY 2020 2nd Quarter are retrospectively adjusted to reflect the revision of the initially allocated amounts of acquisition price.

SUMITOMO CHEMICAL

## Sales Revenue by Business Segment

|  |  |  |  |  |  | of yen |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | FY2020 2nd Quarter | FY2021 <br> 2nd Quarter | Difference | Ratio | Sales price variance | Shipping volume variance | Foreign currency conversion variance |
| Petrochemicals \& Plastics | 243.6 | 399.5 | 155.9 | 64.0\% | 105.5 | 42.4 | 8.0 |
| Energy \& Functional Materials | 105.2 | 148.5 | 43.2 | 41.1\% | 10.0 | 31.0 | 2.3 |
| IT-related Chemicals | 213.3 | 227.7 | 14.4 | 6.8\% | -7.5 | 16.5 | 5.4 |
| Health \& Crop Sciences | 186.1 | 209.4 | 23.4 | 12.6\% | 5.5 | 11.0 | 6.9 |
| Pharmaceuticals | 276.1 | 309.6 | 33.4 | 12.1\% | -3.5 | 30.5 | 6.4 |
| Others \& Adjustments | 22.5 | 30.6 | 8.1 | 36.2\% | 0.0 | 8.1 | 0.0 |
| Total | 1,046.8 | 1,325.2 | 278.4 | 26.6\% | 110.0 | 139.4 | 29.0 |

## Analysis



SUMITOMO CHEMICAL

## Core Operating Income by Business Segment

|  |  |  |  |  | Unit; Billions of yen |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | $\begin{gathered} \text { FY2020 } \\ \text { 2nd Quarter } \end{gathered}$ | FY2021 2nd Quarter | Difference | Price variance | Cost variance | Shipping volume variance and other |
| Petrochemicals \& Plastics | -31.3 | 42.0 | 73.3 | 20.5 | -2.5 | 55.3 |
| Energy \& Functional Materials | 4.8 | 12.6 | 7.8 | -3.0 | 0.5 | 10.3 |
| IT-related Chemicals | 22.1 | 29.5 | 7.4 | -7.5 | -1.0 | 15.9 |
| Health \& Crop Sciences | 9.3 | 18.5 | 9.1 | 2.0 | 1.0 | 6.1 |
| Pharmaceuticals | 49.1 | 50.0 | 0.9 | -3.5 | -24.0 | 28.4 |
| Others \& Adjustments | -0.5 | -3.7 | -3.1 | 0.0 | 0.0 | -3.1 |
| Total | 53.5 | 148.9 | 95.4 | 8.5 | -26.0 | 112.9 |

## Analysis

$$
\begin{aligned}
& +112.9 \\
& \text { Equity in earnings } \\
& +50.2 \text { included }
\end{aligned}
$$



## Petrochemicals \& Plastics - Segment Analysis -

Sales Revenue


## Total $¥ 399.5$ billion (+155.9 from FY2020 2nd Quarter )

Sales price
+105.5
Volume +42.4

Foreign exchange
+8.0

■ Higher market prices

- Increase in shipments of Rabigh products due to periodic shutdown maintenance in the same period of previous fiscal year.
- Recovery of shipments from the lower sales volume in the same period of previous fiscal year due to the COVID-19 pandemic.


## Core Operating Income Total $¥ 42.0$ billion ( +73.3 from FY2020 2nd Quarter )



## Price variance

+20.5
Cost variance
-2.5
Volume variance etc.

- Increase in equity in earnings from investments in affiliates
+55.3
- Increase in profit margin on raw materials for synthetic fibers and synthetic resins
- Recovery of shipments from the lower sales volume in the same period of previous fiscal year due to the COVID-19 pandemic.


## Energy \& Functional Materials - Segment Analysis -

## Sales Revenue



## Total $¥ 148.5$ billion (+43.2 from FY2020 2nd Quarter )

Sales price
+10.0
Volume +31.0

Foreign exchange +2.3

- Higher selling price of aluminum
- Higher selling price of cathode materials
- Increase in shipment of lithium-ion secondary battery separator
- Recovery of shipments from the lower sales volume in the same period of previous fiscal year due to the COVID-19 pandemic.


## Core Operating Income Total ¥12.6 billion (+7.8 from FY2020 2nd Quarter )



## IT-related Chemicals - Segment Analysis -



## Total ¥227.7 billion (+14.4 from FY2020 2nd Quarter )

Sales price $\quad-7.5$
Volume

- Decline in the selling price of polarizing film
- Increase in shipments of processing materials for semiconductors
+16.5
- Increase in shipments of materials for display applications
Foreign exchange

$$
+5.4
$$

## Core Operating Income Total $¥ 29.5$ billion ( +7.4 from FY2020 2nd Quarter )


Price variance

- Decline in the selling price of polarizing film
-7.5
Cost variance
-1.0

Volume variance etc.

- Increase in shipments of processing materials for semiconductors

$$
\text { +15.9 } \begin{aligned}
& \text { Increase in shipments of materials for display } \\
& \text { applications }
\end{aligned}
$$

## Health \& Crop Sciences - Segment Analysis -



## Core Operating Income Total $¥ 18.5$ billion (+9.1 from FY2020 2nd Quarter )



- Increase in profit margin on feed additive methionine

Cost variance
$+1.0$
Volume variance etc.
+6.1

- Rationalization of manufacturing cost of methionine
- Increase in shipments of crop protection products in North America, South America and India


## Pharmaceuticals - Segment Analysis -



Total ¥309.6 billion (+33.4 from FY2020 2nd Quarter )
Sales price

- NHI price revisions in Japan
- Lump-sum revenue from a collaboration and license agreement
- Increase in shipments for Sumitovant
- decrease in shipments of Brovana® and Latuda® in North America


## Core Operating Income Total $¥ 50.0$ billion ( +0.9 from FY2020 2nd Quarter )



## Breakdown of Non-recurring Items

Unit; Billions of yen

|  | FY2020 <br> 2nd Quarter | FY2021 <br> 2nd Quarter | Difference |
| :--- | :---: | :---: | :---: |
| Restructuring charges | -2.6 | $\mathbf{- 3 . 0}$ | -0.4 |
| Impairment loss | - | $\mathbf{- 1 . 6}$ | -1.6 |
| Changes in fair value of contingent consideration | 0.1 | $\mathbf{- 0 . 1}$ | -0.2 |
| Others | -0.8 | $\mathbf{0 . 1}$ | 0.9 |
| Non-recurring items | -3.3 | $\mathbf{- 4 . 6}$ | $\mathbf{- 1 . 3}$ |

## Consolidated Balance Sheets

|  | 31-Mar-21 | 30-Sep-21 | Difference |
| :---: | :---: | :---: | :---: |
| Current assets | 1,584.5 | 1,682.4 | 98.0 |
| Cash and cash equivalents | 360.9 | 346.8 | -14.1 |
| Trade and other receivables | 652.6 | 674.1 | 21.5 |
| Inventories | 511.5 | 586.9 | 75.4 |
| Others | 59.4 | 74.6 | 15.2 |
| Non-current assets | 2,405.8 | 2,400.4 | -5.4 |
| Property, plant and equipment | 793.5 | 798.0 | 4.5 |
| Goodwill and Intangible assets | 670.5 | 666.9 | -3.6 |
| Others | 941.8 | 935.5 | -6.4 |
| Total | 3,990.3 | 4,082.8 | 92.5 |


| Unit; Billions of yen |  |  |  |
| :---: | :---: | :---: | :---: |
|  | 31-Mar-21 | 30-Sep-21 | Difference |
| Liabilities | 2,508.1 | 2,535.0 | 26.9 |
| Trade and other payables | 522.9 | 540.3 | 17.4 |
| Interest-bearing Liabilities | 1,351.1 | 1,358.1 | 7.0 |
| Others | 634.2 | 636.7 | 2.5 |
| Equity | 1,482.1 | 1,547.8 | 65.6 |
| Shareholders' equity | 962.8 | 1,042.3 | 79.5 |
| Other components of equity | 56.4 | 38.6 | -17.9 |
| Non-controlling interests | 462.9 | 466.9 | 4.0 |
| Total | 3,990.3 | 4,082.8 | 92.5 |
| Equity attributable to owners of parent to total assets | 25.5\% | 26.5\% | 1.0\% |
| D/E ratio (times) | 0.9 | 0.9 | 0.0 |

## Consolidated Statements of Cash Flows

|  | Unit; Billions of yen |  |  |
| :---: | :---: | :---: | :---: |
|  | FY2020 2nd Quarter | FY2021 2nd Quarter | Difference |
| Cash flows from operating activities | 156.6 | 77.2 | -79.4 |
| Cash flows from investing activities | -63.0 | -65.2 | -2.2 |
| Free cash flows | 93.6 | 12.0 | -81.6 |
| Cash flows from financing activities | 97.9 | -27.1 | -125.1 |
| Effect of exchange rate changes on cash and cash equivalents | 9.6 | 1.0 | -8.6 |
| Net change in cash and cash equivalents | 201.2 | -14.1 | -215.3 |
| Cash and cash equivalents at end of period | 381.8 | 346.8 | -35.0 |

## 2. Outlook for FY2021

## Financial Estimates for Year

|  |  |  |  |  | Unit; Billions of yen |
| :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Previous Estimates | Revised Estimates | Difference | Ratio |
| Sales revenue |  | 2,610.0 | 2,710.0 | 100.0 | 3.8\% |
| Core operating incom |  | 200.0 | 245.0 | 45.0 | 22.5\% |
| (Non-recurring items) |  | (-20.0) | (-20.0) | - | - |
| Operating income |  | 180.0 | 225.0 | 45.0 | 25.0\% |
| Net income attributab | wners of the parent | 100.0 | 140.0 | 40.0 | 40.0\% |
| ROE |  | 9.6\% | 13.1\% |  |  |
| Exchange rate(yen/\$) |  | 110.00 | $\begin{array}{r} 109.91 \\ \text { (2nd Half } 110.00 \text { ) } \end{array}$ |  |  |
| Naphtha price(yen/K |  | 47,000 | $\begin{array}{r} 50,300 \\ \text { (2nd Half } 50,000 \text { ) } \end{array}$ |  |  |
|  | Interim dividend | 10.00 | 10.00 |  |  |
| Cash dividends (yen) | Year-end dividend | 10.00 | 14.00 |  |  |
|  | Annual dividend | 20.00 | 24.00 |  |  |

## Sales Revenue and Core Operating Income by Business Segment

Unit; Billions of yen

|  | Sales revenue |  |  | Core operating income |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Previous Estimates | Revised Estimates | Difference | Previous Estimates | Revised Estimates | Difference |
| Petrochemicals \& Plastics | 760.0 | 810.0 | 50.0 | 36.0 | 64.0 | 28.0 |
| Energy \& Functional Materials | 280.0 | 305.0 | 25.0 | 19.0 | 23.0 | 4.0 |
| IT-related Chemicals | 435.0 | 450.0 | 15.0 | 40.0 | 48.0 | 8.0 |
| Health \& Crop Sciences | 460.0 | 470.0 | 10.0 | 38.0 | 43.0 | 5.0 |
| Pharmaceuticals | 610.0 | 610.0 | - | 67.0 | 67.0 | - |
| Others \& Adjustments | 65.0 | 65.0 | - | 0.0 | 0.0 | - |
| Total | 2,610.0 | 2,710.0 | 100.0 | 200.0 | 245.0 | 45.0 |

## (Reference: Segment Information)

## Cost Elements etc.

|  | $\begin{array}{c}\text { FY2020 } \\ \text { 2nd Quarter; Billions of yen }\end{array}$ |  |
| :--- | ---: | ---: | ---: |
| 2nd Quarter |  |  |$)$ Difference

[^0]As a result, figures for FY 2020 2nd Quarter are retrospectively adjusted to reflect the revision of the initially allocated amounts of acquisition price.

## Capital Expenditures by Business Segment

Unit; Billions of yen

|  | FY2020 <br> 2nd Quarter | FY2021 <br> 2nd Quarter | Difference |
| :--- | ---: | ---: | ---: |
| Petrochemicals \& Plastics | 10.1 | $\mathbf{1 0 . 2}$ | 0.1 |
| Energy \& Functional Materials | 14.1 | $\mathbf{1 1 . 8}$ | $\mathbf{- 2 . 4}$ |
| IT-related Chemicals | 6.3 | $\mathbf{6 . 1}$ | $\mathbf{- 0 . 2}$ |
| Health \& Crop Sciences | 8.2 | $\mathbf{8 . 5}$ | 0.3 |
| Pharmaceuticals | 6.0 | $\mathbf{8 . 5}$ | $\mathbf{2 . 6}$ |
| Others \& Adjustments | 13.1 | $\mathbf{5 . 9}$ | $\mathbf{- 7 . 2}$ |
| Total | 57.8 | $\mathbf{5 1 . 0}$ | $\mathbf{- 6 . 8}$ |

## Depreciation and Amortization by Business Segment

Unit; Billions of yen

|  | FY2020 <br> 2nd Quarter | FY2021 <br> 2nd Quarter | Difference |
| :--- | ---: | ---: | ---: | ---: |
| Petrochemicals \& Plastics | 13.2 | $\mathbf{1 3 . 4}$ | 0.2 |
| Energy \& Functional Materials | 8.4 | $\mathbf{9 . 4}$ | 1.0 |
| IT-related Chemicals | 12.5 | $\mathbf{1 3 . 8}$ | 1.3 |
| Health \& Crop Sciences | 13.6 | $\mathbf{1 3 . 4}$ | $\mathbf{- 0 . 2}$ |
| Pharmaceuticals | 11.0 | $\mathbf{1 9 . 6}$ | $\mathbf{8 . 6}$ |
| Others \& Adjustments | 6.7 | $\mathbf{8 . 1}$ | 1.5 |
| Total | 65.3 | $\mathbf{7 7 . 7}$ | 12.4 |

※ During FY 2020, we finalized the provisional accounting treatment for business combinations.
As a result, figures for FY 2020 2nd Quarter are retrospectively adjusted to reflect the revision of the initially allocated amounts of acquisition price.

## Research \& Development Expenses by Business Segment

Unit; Billions of yen

|  | FY2020 <br> 2nd Quarter | FY2021 <br> 2nd Quarter | Difference |
| :--- | ---: | ---: | ---: |
| Petrochemicals \& Plastics | 3.3 | $\mathbf{3 . 4}$ | 0.1 |
| Energy \& Functional Materials | 4.0 | $\mathbf{3 . 8}$ | $\mathbf{- 0 . 2}$ |
| IT-related Chemicals | 8.9 | $\mathbf{9 . 6}$ | 0.7 |
| Health \& Crop Sciences | 13.0 | $\mathbf{1 2 . 2}$ | $\mathbf{- 0 . 9}$ |
| Pharmaceuticals | 50.3 | $\mathbf{4 6 . 9}$ | $\mathbf{- 3 . 4}$ |
| Others \& Adjustments | $\mathbf{7 . 4}$ | $\mathbf{7 . 9}$ | $\mathbf{0 . 5}$ |
| Total | $\mathbf{8 6 . 9}$ | $\mathbf{8 3 . 8}$ | $\mathbf{- 3 . 1}$ |

## Sales Revenue by Business Segment (Quarterly)

|  |  |  |  |  |  |  | Unit; Billions of yen |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | FY2020 |  |  |  | FY2021 |  | FY2021(Estimates) |  |
|  | 1Q | 2Q | 3 Q | 4Q | 1 Q | 2Q | 1st Half | 2nd Half |
| Petrochemicals \& Plastics | 108.2 | 135.4 | 164.8 | 180.9 | 199.5 | 200.0 | 399.5 | 410.5 |
| Energy \& Functional Materials | 48.3 | 56.9 | 70.1 | 69.9 | 74.4 | 74.1 | 148.5 | 156.5 |
| IT-related Chemicals | 103.8 | 109.4 | 111.0 | 107.6 | 109.3 | 118.4 | 227.7 | 222.3 |
| Health \& Crop Sciences | 88.9 | 97.2 | 96.4 | 140.6 | 103.1 | 106.4 | 209.4 | 260.6 |
| Pharmaceuticals | 140.8 | 135.4 | 141.4 | 128.9 | 139.2 | 170.4 | 309.6 | 300.4 |
| Others \& Adjustments | 10.1 | 12.3 | 12.1 | 16.5 | 13.6 | 17.0 | 30.6 | 34.4 |
| Total | 500.2 | 546.6 | 595.8 | 644.4 | 639.0 | 686.2 | 1,325.2 | 1,384.8 |

## Core Operating Income by Business Segment (Quarterly)


※ During FY 2020, we finalized the provisional accounting treatment for business combinations.
As a result, figures for FY 2020 are retrospectively adjusted to reflect the revision of the initially allocated amounts of acquisition price.

## Major Group Companies

\begin{tabular}{|c|c|c|c|}
\hline \multirow[b]{2}{*}{Company} \& \multicolumn{2}{|l|}{Sales Revenue} \& \multirow[b]{2}{*}{Profit Trends} \\
\hline \& \[
\begin{array}{c|}
\hline \text { FY2020 } \\
\text { 2nd Quarter } \\
\hline
\end{array}
\] \& \[
\begin{array}{|c|}
\text { FY2021 } \\
\text { 2nd Quarter }
\end{array}
\] \& \\
\hline \begin{tabular}{l}
The Polyolefin Company (Singapore) \\
(Millions of USD)
\end{tabular} \& 416 \& 600 \& Despite periodic shutdown maintenance in the current quarter, profit margins improved. \\
\hline \begin{tabular}{l}
Petrochemical Corporation of Singapore \\
(Millions of USD)
\end{tabular} \& 875 \& 1,307 \& Due to periodic shutdown maintenance and a slight deterioration in profit margins. \\
\hline \begin{tabular}{l}
Rabigh Refining and Petrochemical Company \\
(Millions of SAR)
\end{tabular} \& 6,768 \& 21,245 \& \begin{tabular}{l}
Largely due to periodic shutdown \\
maintenance in last fiscal year, and Improved margins on oil refining and petrochemical products.
\end{tabular} \\
\hline Dongwoo Fine-Chem

(Billions of KRW) \& 1,315.4 \& 1,242.6 \& Decrease in profit due to a change in product mix. <br>

\hline | Valent U.S.A. and Subsidiaries |
| :--- |
| (Millions of USD) | \& 303 \& 352 \& Profit increased due to higher shipment volume and other factors. <br>

\hline
\end{tabular}

## Crop Protection Product Sales by Region

Unit; Billions of yen

|  | FY2020 <br> 2nd Quarter | FY2021 <br> 2nd Quarter | Difference | Reasons for Change |
| :---: | :---: | :---: | :---: | :---: |
| Japan | 28.0 | 29.6 | 1.5 | Increase in shipments due to the high incidence of paddy rice diseases |
| North America | 18.7 | 22.8 | 4.1 | Increase in shipments due to the decrease of distribution inventories |
| Central \& South America | 50.9 | 55.1 | 4.2 | Increase in shipments due to market growth in Brazil and others |
| Asia (including India) | 25.5 | 27.0 | 1.5 | - Increase in shipments in India <br> -Foreign currency conversion variance |
| Europe \& Others | 7.3 | 9.2 | 1.9 | - Increase in shipments due to the decrease of distribution inventories -Foreign currency conversion variance |
| Total | 130.5 | 143.6 | 13.1 |  |


[^0]:    ※ During FY 2020, we finalized the provisional accounting treatment for business combinations.

